{"id":393,"date":"2012-03-01T00:00:41","date_gmt":"2012-03-01T07:00:41","guid":{"rendered":"http:\/\/rhochistj.org\/RCP_TEST\/?p=393"},"modified":"2014-02-04T21:54:54","modified_gmt":"2014-02-05T04:54:54","slug":"jentadueto-approved-by-fda-for-type-2-diabetes-mellitus","status":"publish","type":"post","link":"https:\/\/rhochistj.org\/RhoChiPost\/jentadueto-approved-by-fda-for-type-2-diabetes-mellitus\/","title":{"rendered":"Jentadueto Approved by FDA for Type 2 Diabetes Mellitus"},"content":{"rendered":"<p>By: Ebey P. Soman<\/p>\n<p>&#8211;<\/p>\n<p>The FDA recently approved a combination tablet of linagliptin with metformin hydrochloride (Jentadueto\u00ae) for the treatment of type 2 diabetes. \u00a0Developed by Boehringer Ingelheim and Eli Lilly, the new combination tablet provides a twice-daily treatment option for healthcare providers looking for greater flexibility in treating diabetes.<\/p>\n<p>Prescribers may add a sulfonylurea to linagliptin\/metformin for greater glycemic control. \u00a0Placebo-controlled trials demonstrated that the drug lowers hemoglobin A1C levels by 1.7%. \u00a0The most common side effects (<span style=\"text-decoration: underline;\">&gt;<\/span>5%) were nasopharyngitis and diarrhea. \u00a0Linagliptin\/metformin did not cause any weight gain, unlike other treatment options (such as thiazolidinediones and certain insulins). \u00a0Hypoglycemia is still a risk factor for patients treated with linagliptin\/metformin and sulfonylurea. \u00a0As with other \u201cgliptins,\u201d pancreatitis is still a possible adverse effect. \u00a0The drug also carries a Black Box Warning for the risk of lactic acidosis, particularly because of the metformin component.<\/p>\n<p>There are no studies regarding the safety profile of the drug when used in conjunction with insulin. \u00a0Clinical trials demonstrating the efficacy of linagliptin\/metformin examined separate administrations of linagliptin and metformin. \u00a0Researchers determined bioequivalence by co-administrating separate linagliptin and metformin tablets.\u00a0 It would be interesting to see more safety and efficacy trials for this drug based upon the combination tablet, and not the co-administration of linagliptin and metformin.<\/p>\n<p>Jentadueto\u00ae will be available in pharmacies by this summer.<\/p>\n<p><b><span style=\"text-decoration: underline;\">SOURCES:<\/span><\/b><\/p>\n<ol>\n<li>Jentadueto [linagliptin and metformin hydrochloride] package insert.<\/li>\n<li>Formulary staff. FDA approves tablets for adult patients with type 2 diabetes. Website. Available online: <a href=\"http:\/\/formularyjournal.modernmedicine.com\/formulary\/FDA+Approvals\/FDA-approves-tablets-for-adult-patients-with-type-\/ArticleStandard\/Article\/detail\/757904?contextCategoryId=44276\" class=\"external external_icon\">http:\/\/formularyjournal.modernmedicine.com\/formulary\/FDA+Approvals\/FDA-approves-tablets-for-adult-patients-with-type-\/ArticleStandard\/Article\/detail\/757904?contextCategoryId=44276<\/a>. 2012 Feb. Last accessed Feb 29, 2012.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>By: Ebey P. Soman &#8211; The FDA recently approved a combination tablet of linagliptin with metformin hydrochloride (Jentadueto\u00ae) for the treatment of type 2 diabetes. \u00a0Developed by Boehringer Ingelheim and Eli Lilly, the new combination tablet provides a twice-daily treatment option for healthcare providers looking for greater flexibility in treating diabetes. Prescribers may add a&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,5],"tags":[343,1623,1160,198,2238,13,2227,420,2232,314,342,71,1193,1194,344,363,36,187,236,321,16,623,59,1061],"class_list":["post-393","post","type-post","status-publish","format-standard","hentry","category-clinical","category-news-politics","tag-and","tag-combination","tag-control","tag-daily","tag-diabetes","tag-drug","tag-ebola-virus-disease","tag-factor","tag-fda","tag-for","tag-hydrochloride","tag-insulin","tag-jentadueto","tag-linagliptin","tag-metformin","tag-of","tag-risk","tag-side","tag-tablet","tag-tablets","tag-treatment","tag-type","tag-weight","tag-with"],"views":613,"_links":{"self":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/393","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/comments?post=393"}],"version-history":[{"count":0,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/393\/revisions"}],"wp:attachment":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/media?parent=393"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/categories?post=393"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/tags?post=393"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}